Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 4Leukemia, Lymphocytic, Chronic, B-Cell 3Neoplasms 2Hematologic Neoplasms 2Rare Diseases 1Neurologic Manifestations 1Neuroblastoma 1Neoplasms, Plasma Cell 1Myasthenia Gravis 1Mental Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphoma 1Leukemia 1Infections 1Burkitt Lymphoma 1Agammaglobulinemia 1

Interventions

Cyclophosphamide 217Rituximab 110Etoposide 99Peripheral Blood Stem Cell Transplantation 93Vincristine 91Filgrastim 91Methotrexate 90Cytarabine 90fludarabine phosphate 84Radiotherapy 67Doxorubicin 67Prednisone 66Dexamethasone 57Cyclosporine 53Mycophenolic Acid 52Whole-Body Irradiation 49Busulfan 46Melphalan 44blinatumomab 43fludarabine 41Tacrolimus 41Antilymphocyte Serum 40Methylprednisolone 39merphos 35Calcium Dobesilate 34Leucovorin 33Granulocyte Colony-Stimulating Factor 30Mercaptopurine 26dexamethasone acetate 25dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Burkitt Lymphoma × Immunoglobulins × Clear all
NCT05453500 2026-05-11

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

University of Washington

Phase 2 Active not recruiting
32 enrolled
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡